<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="recognize">
            <roleset id="recognize.01" name="" wordnet="3">
                <roles>
                    <role n="0" descr="agent&#x0A;" />
                    <role n="1" descr="thing being identified&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>A monoclonal antibody that recognizes STAT1 N-terminus is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), will recognize the promoter of the ribosomal RNA gene and activate RNA polymerase I-mediated transcription through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">the promoter of the ribosomal RNA gene</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>A0 (the upstream eukaryotic binding factor (UBF), recognized the promoter of the RNA ribosomal gene and activated RNA-mediated transcription polymerase I through cooperative interactions with the species specific factor, SL1.</text>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by this antibody in PKR+/+MEFs are the ones indicated.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Blots were surveyed with anti-LMP-1 antisembly purified recognizing epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>Exactly, it is not clear how specific A1 sites will be recognized during the processing of the precursor RNA complex.</text>
                </example>
                <example src="EGRAM" no="6">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where STAT1 N-terminus was recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>NarL protein binds to these sites 7-2-7, but, unlike NarP, it also recognizes heptamers in other arrangements .</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>The blots were probed with anti-LMP-1 anti-LMP-1 purified affinity that can recognize epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>The blots were probed with polyclonal anti-LMP-1 affinity antiserum recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antiserum</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with monoclonal antibody that recognizes STAT1 N-terminus and by western blotting.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>We show that activator complex cAMP-CRP will recognize two sites in tsx-p2 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>a monoclonal antibody that has recognized STAT1 N-terminus was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle has been recognized by D1 antibody of anti-64kD human autoantigen.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>anti-LMP-1 purified affinity antiserum recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution are recognized by anti-LMP-1 antisembly purified with which the wires were probed.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>most of the regulators belonging to the AraC/XylS family can recognize multiple connection site in regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>the lowest form of Stat3, Stat3Beta could be recognized in immunoprecipitatio with anti-Stat3 pAb, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>the lowest form of Stat3, Stat3Beta was recognized in the immunoprecipitatome with anti-Stat3 pAb, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>the lowest form of Stat3, Stat3Beta, cannot is recognized in immunoprecipitatio with anti-Stat3 pAb, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>the promoter of the RNA ribosomal gene was recognized by the eukaryotic binding factor upstream (UBF).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>two sites in tsx-p2 were recognized by the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>A monoclonal antibody has also joined these 727 sites but, unlike NarP, has also recognized STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>A monoclonal antibody that recognizes STAT1 N-terminus is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), recognized the promoter of the ribosomal RNA gene and activated the transcription mediated by RNA polymerase I through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">the promoter of the ribosomal RNA gene</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>A0 (the upstream eukaryotic binding factor (UBF), recognized sequence (YPYDVPDYA) at a dilution 1:500 and activated RNA-mediated transcription polymerase I through cooperative interactions with the species specific factor, SL1.</text>
                    <arg n="1">sequence (YPYDVPDYA) at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>A0 (the upstream eukaryotic binding factor (UBF), recognized the promoter of the ribosomal RNA gene and activated RNA polymerase I-mediated transcription through cooperative interactions with the species specific factor, SL1.</text>
                    <arg n="1">the promoter of the ribosomal RNA gene</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by polyclonal anti-LMP-1 purified affinity antiserum are indicated.</text>
                    <arg n="0">polyclonal anti-LMP-1 purified affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by polyclonal anti-LMP-1 purified affinity antiserum are the ones indicated.</text>
                    <arg n="0">polyclonal anti-LMP-1 purified affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Blots were surveyed with NarL protein recognizing heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Blots were surveyed with NarL protein recognizing heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Blots were surveyed with anti-LMP-1 anti-LMP-1 purified affinity recognizing epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Blots were surveyed with anti-LMP-1 purified affinity antiserum recognizing epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Blots were surveyed with anti-Stat3 pAb recognizing the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Blots were surveyed with most of the regulators belonging to the AraC/XylS family recognizing multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>C-term of CD40 at a 1:500 dilution could be recognized in immunoprecipitatio with polyclonal anti-CD40 anti-rabbit antisound, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>C-term of CD40 at a 1:500 dilution has been recognized by polyclonal anti-CD40 anti-rabbit antisound.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>D1 anti-64kD human autoantigen can recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle in regulated promoters.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>D1 anti-64kD human autoantigen recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>D1 anti-64kD human autoantigen that has recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>D1 antibody of anti-64kD human autoantigen binds to these sites 7-2-7, but, unlike NarP, it also recognizes a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle .</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>D1 antibody of anti-64kD human autoantigen recognizes a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>D1 antibody of anti-64kD human autoantigen will recognize a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle in regulated promoters.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>D1 antibody of human autoantigen anti-64kD that recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>D1 antibody of human autoantigen anti-64kD that recognizes polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that NarL protein can recognize heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that activator complex cAMP-CRP can recognize two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum can recognize epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that monoclonal antibody can recognize STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family can recognize multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family can recognize multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that D1 antibody of anti-64kD human autoantigen recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that NarL protein recognized heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum has recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum has recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that monoclonal antibody has recognized N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that proteins has recognized short reasons within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the NarL protein has recognized heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the NarL protein recognized heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the upstream eukaryotic binding factor (UBF) has recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the upstream eukaryotic binding factor (UBF) recognized the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where N-terminus STAT1 is recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epitopes in the C muscle of LMP-1 at a dilution of 1:200 is recognized by polyclonal anti-LMP-1 affinity antisumption.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where heptameric in other arrangements is recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where heptamers in other arrangements was recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where multi-binding sites was recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where short reasons within the protected region is recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where the RNA ribosomal gene promoter is recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where two sites in tsx-p2 is recognized by the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where two sites in tsx-p2 was recognized by activating complex cAMP-CRP.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where two sites in tsx-p2 was recognized by the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with a monoclonal antibody which recognized STAT1 N-terminus and by the western inflorescence.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with activator complex cAMP-CRP which recognized two sites in tsx-p2, and by Western blotting</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-64kD antibodies of human autoantigen D1 which recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle and by the western inflorescence.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-64kD antibodies of human autoantigen D1 which recognizes polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle, and by Western blotting</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit which recognized term C of CD40 at a dilution 1:500, and by Western blotting</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 anti-LMP-1 purified affinity which recognizes epitopes in the terminal C of LMP-1 at a 1:200 dilution, and by Western blotting</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 antisembly purified which recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution, and by Western blotting</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with monoclonal antibody which recognized STAT1 N-terminus and by the western inflorescence.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with monoclonal antibody which recognized STAT1 N-terminus, and by Western blotting</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most of the regulators belonging to the AraC/XylS family which recognized multiple linkage site and by the western inflorescence.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most of the regulators belonging to the AraC/XylS family which recognized multiple-link location, and by Western blotting</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most of the regulators belonging to the AraC/XylS family which recognizes multi-binding sites, and by Western blotting</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most of the regulators belonging to the AraC/XylS family which recognizes multiple connection site, and by Western blotting</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most regulators belonging to the AraC/XylS family which recognized multiple binding sites and by the western inflorescence.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with proteins which recognized short reasons within the protected region, and by Western blotting</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the activator complex cAMP-CRP which recognizes two sites in tsx-p2, and by Western blotting</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the eukaryotic binding factor upstream (UBF) which recognized the promoter of the RNA ribosomal gene, and by Western blotting</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the eukaryotic binding factor upstream (UBF) which recognizes the promoter of the RNA ribosomal gene, and by Western blotting</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where epictopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where heptamers in other arrangements was recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where multi-binding sites was recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where short motives within the protected region was recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where the STAT1 N-terminal was recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>It is shown that D1 antibody of human autoantigen anti-64kD has recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>It is shown that activator complex cAMP-CRP has recognized two sites in tsx-p2 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>It is shown that anti-LMP-1 antisembly purified has recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>It is shown that proteins has recognized short motives within the protected region that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>N-terminus STAT1 is recognized by monoclonal antibody that the litters were probed.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>N-terminus STAT1 was recognized in the immunoprecipitatome with monoclonal antibody, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>NarL protein also binds to these 727 sites but, unlike NarP, also recognized heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>NarL protein also binds to these sites 7-2-7, but, unlike NarP, it also recognized heptameric in other arrangements .</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>NarL protein are able to recognize heptamers in other arrangements in regulated promoters.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>NarL protein can recognize heptamers in other arrangements in regulated promoters.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>NarL protein recognized heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>NarL protein that has recognized heptameric in other arrangements was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>NarL protein that recognizes heptamers in other arrangements is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>NarL protein will recognize heptamers in other arrangements in regulated promoters.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that A monoclonal antibody are able to recognize STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that a monoclonal antibody has recognized STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that activating the cAMP-CRP complex are able to recognize two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that activator complex cAMP-CRP can recognize two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-64kD antibodies of human autoantigen D1 are able to recognize a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-64kD antibodies of human autoantigen D1 are able to recognize polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit has recognized term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 anti-LMP-1 purified affinity recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 antisembly purified can recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 antisembly purified has recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum can recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-Stat3 pAb recognized the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that monoclonal antibody are able to recognize STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that monoclonal antibody has recognized STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family can recognize multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most regulators belonging to the AraC/XylS family recognized multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the cAMP-CRP activator complex are able to recognize two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the cAMP-CRP activator complex can recognize two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the upstream eukaryotic binding factor (UBF) can recognize the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that NarL protein are able to recognize heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that a monoclonal antibody are able to recognize STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit are able to recognize term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that most of the regulators belonging to the AraC/XylS family are able to recognize multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>STAT1 N-terminal are recognized by monoclonal antibody with which the threads were probed.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>STAT1 N-terminal are recognized by monoclonal antibody with which the wires were probed.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>STAT1 N-terminal, could be recognized in the immunoprecipitaiton with monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>STAT1 N-terminus is recognized by a monoclonal antibody that the litters were probed.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>STAT1 N-terminus is recognized by monoclonal antibody by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>STAT1 N-terminus was recognized by a monoclonal antibody by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>STAT1 N-terminus was recognized by monoclonal antibody by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>STAT1 N-terminus were recognized by A monoclonal antibody.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>STAT1 N-terminus were recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>STAT1 N-terminus will be recognized by the a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>STAT1 N-terminus, cannot is recognized in immunoprecipitatio with A monoclonal antibody, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>STAT1 N-terminus, cannot is recognized in immunoprecipitatio with monoclonal antibody, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>STAT1 N-terminus, cannot is recognized in the immunoprecipitaiton with monoclonal antibody as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>The STAT1 N-terminal is recognized by the monoclonal antibody that the garbage was surveyed.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>The STAT1 N-terminus is recognized by the monoclonal antibody that the garbage was surveyed.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>The STAT1 N-terminus was recognized by the monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>The a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle was recognized by the anti-64kD antibodies of human autoantigen D1 acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>The a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle was recognized by the anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>The blots were investigated with anti-64kD antibodies of human autoantigen D1 that recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>The blots were investigated with anti-LMP-1 antisembly purified that recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>The blots were investigated with anti-LMP-1 purified affinity antiserum that recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>The blots were investigated with most of the regulators belonging to the AraC/XylS family that recognized multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>The blots were investigated with the activator complex cAMP-CRP that recognized two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>The blots were investigated with the upstream eukaryotic binding factor (UBF) that recognized the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>The blots were investigated with the upstream eukaryotic binding factor (UBF) that recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>The blots were probed with NarL protein that can recognize heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>The blots were probed with a monoclonal antibody that can recognize STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>The blots were probed with activator complex cAMP-CRP that can recognize two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>The blots were probed with anti-LMP-1 antisumption of affinity recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisumption of affinity</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>The blots were probed with most of the regulators belonging to the AraC/XylS family that can recognize multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>The blots were probed with most of the regulators belonging to the AraC/XylS family that can recognize multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>The blots were probed with polyclonal anti-CD40 anti-rabbit antisound that can recognize C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>The blots were probed with the activator complex cAMP-CRP that can recognize two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>The blots were probed with the eukaryotic binding factor upstream (UBF) that can recognize the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>The blots were probed with the upstream eukaryotic binding factor (UBF) that can recognize the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>The epictopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by the anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>The epiptopes in the C-terminal of LMP-1 at a 1:200 dilution was recognized by the anti-LMP-1 anti-LMP-1 purified affinity acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>The epitoped in the C-terminal of LMP-1 in a 1:200 dilution is recognized by the anti-LMP-1 antisembly purified that the garbage was surveyed.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>The epitopes in the C muscle of LMP-1 at a dilution of 1:200 was recognized by the polyclonal anti-LMP-1 affinity antisumption acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>The heptameric in other arrangements was recognized by the NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>The heptamers in other arrangements is recognized by the NarL protein that the garbage was surveyed.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with A monoclonal antibody that recognizes STAT1 N-terminus and by western blotting.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with D1 anti-64kD human autoantigen that recognizes polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle and by western blotting.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with D1 antibody of anti-64kD human autoantigen that recognizes a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle and by western blotting.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with activator complex cAMP-CRP that recognizes two sites in tsx-p2 and by western blotting.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit that recognizes term C of CD40 at a dilution 1:500 and by western blotting.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with monoclonal antibody that recognizes N-terminus STAT1 and by western blotting.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with polyclonal anti-LMP-1 affinity antisumption that recognizes epitopes in the C muscle of LMP-1 at a dilution of 1:200 and by western blotting.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with the NarL protein that recognizes heptamers in other arrangements and by western blotting.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with the activator complex cAMP-CRP that recognizes two sites in tsx-p2 and by western blotting.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where C-term of CD40 at a 1:500 dilution is recognized by polyclonal anti-CD40 anti-rabbit antisound.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where heptameric in other arrangements is recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where heptamers in other arrangements is recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where the promoter of the RNA ribosomal gene is recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where two sites in tsx-p2 is recognized by the activator complex cAMP-CRP.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>The multiple binding sites was recognized by the most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>The multiple connection site is recognized by the most of the regulators belonging to the AraC/XylS family that the garbage was surveyed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>The multiple connection site was recognized by the most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>The multiple linkage site was recognized by the most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>The polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle was recognized by the anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>The short motives within the protected region was recognized by the proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>The the RNA ribosomal gene promoter was recognized by the the upstream eukaryotic binding factor (UBF) acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>The the STAT1 N-terminal was recognized by the a monoclonal antibody acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>The the STAT1 N-terminal was recognized by the a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>The the lowest form of Stat3, Stat3Beta was recognized by the anti-Stat3 pAb acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>The the lowest form of Stat3, Stat3Beta was recognized by the anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>The the promoter of the RNA ribosomal gene was recognized by the the upstream eukaryotic binding factor (UBF) acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>The two sites in tsx-p2 is recognized by the activating complex cAMP-CRP that the garbage was surveyed.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>The two sites in tsx-p2 was recognized by the activator complex cAMP-CRP.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>We show that A monoclonal antibody will recognize STAT1 N-terminus that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>We show that D1 antibody of human autoantigen anti-64kD recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>We show that D1 antibody of human autoantigen anti-64kD recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>We show that NarL protein recognized heptameric in other arrangements that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>We show that NarL protein will recognize heptameric in other arrangements that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>We show that NarL protein will recognize heptamers in other arrangements that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>We show that a monoclonal antibody recognized the STAT1 N-terminal that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>We show that a monoclonal antibody will recognize STAT1 N-terminus that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>We show that activating complex cAMP-CRP will recognize two sites in tsx-p2 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>We show that activating the cAMP-CRP complex recognized two sites in tsx-p2 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>We show that activating the cAMP-CRP complex will recognize two sites in tsx-p2 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>We show that anti-64kD antibodies of human autoantigen D1 will recognize a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>We show that anti-LMP-1 anti-LMP-1 purified affinity recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>We show that anti-LMP-1 anti-LMP-1 purified affinity recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>We show that anti-LMP-1 antisembly purified recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>We show that anti-LMP-1 antisembly purified will recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>We show that anti-LMP-1 purified affinity antiserum recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>We show that anti-LMP-1 purified affinity antiserum recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>We show that anti-LMP-1 purified affinity antiserum will recognize epictopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>We show that monoclonal antibody recognized STAT1 N-terminus that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>We show that most of the regulators belonging to the AraC/XylS family will recognize multi-binding sites that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>We show that most of the regulators belonging to the AraC/XylS family will recognize multiple connection site that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>We show that most of the regulators belonging to the AraC/XylS family will recognize multiple connection site that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>We show that most regulators belonging to the AraC/XylS family recognized multiple binding sites that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>We show that most regulators belonging to the AraC/XylS family will recognize multiple binding sites that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>We show that polyclonal anti-CD40 anti-rabbit antisound recognized C-term of CD40 at a 1:500 dilution that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>We show that proteins recognized short motives within the protected region that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>a monoclonal antibody also binds to these 727 sites but, unlike NarP, also recognized STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>a monoclonal antibody that recognizes the STAT1 N-terminal is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle is recognized by D1 antibody of anti-64kD human autoantigen that the litters were probed.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle will be recognized by D1 antibody of anti-64kD human autoantigen.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle is recognized by anti-64kD antibodies of human autoantigen D1 that the litters were probed.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle was recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle, was not recognized in the immunoprecipitaiton with anti-64kD antibodies of human autoantigen D1 as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle, will be recognized in the immunoprecipitaiton with anti-64kD antibodies of human autoantigen D1 as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>activating complex cAMP-CRP recognized two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>activating complex cAMP-CRP that recognizes two sites in tsx-p2 is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>activating the cAMP-CRP complex also binds to these sites 7-2-7, but, unlike NarP, it also recognized two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>activating the cAMP-CRP complex has also joined these 727 sites but, unlike NarP, has also recognized two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>activating the cAMP-CRP complex recognized two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>activator complex cAMP-CRP also binds to these 727 sites but, unlike NarP, also recognized two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>activator complex cAMP-CRP recognized two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>activator complex cAMP-CRP recognized two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>activator complex cAMP-CRP recognizes two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>anti-64kD antibodies of human autoantigen D1 recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>anti-64kD antibodies of human autoantigen D1 that has recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>anti-64kD antibodies of human autoantigen D1 that recognizes a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>anti-64kD antibodies of human autoantigen D1 will recognize a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle in regulated promoters.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit binds to these 727 sites but, unlike NarP, will also recognize term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit can recognize term C of CD40 at a dilution 1:500 in regulated promoters.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity also binds to these sites 7-2-7, but, unlike NarP, it also recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution .</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity are able to recognize epitopes in the terminal C of LMP-1 at a 1:200 dilution in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity specifically recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>anti-LMP-1 antisembly purified binds to these sites 7-2-7, but, unlike NarP, it also recognizes epiptopes in the C-terminal of LMP-1 at a dilution 1:200 .</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>anti-LMP-1 antisembly purified that recognizes epitoped in the C-terminal of LMP-1 in a 1:200 dilution is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>anti-LMP-1 purified affinity antiserum also binds to these sites 7-2-7, but, unlike NarP, it also recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 .</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>anti-LMP-1 purified affinity antiserum also binds to these sites 7-2-7, but, unlike NarP, it also recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>anti-LMP-1 purified affinity antiserum are able to recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200 in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>anti-LMP-1 purified affinity antiserum that has recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200 was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>anti-LMP-1 purified affinity antiserum that recognizes epictopes in the C-terminal of LMP-1 at a dilution 1:200 is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>anti-LMP-1 purified affinity antiserum will recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200 in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>anti-Stat3 pAb has also joined these 727 sites but, unlike NarP, has also recognized the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>anti-Stat3 pAb recognized the lowest form of Stat3, Stat3Beta in regulated promoters.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>anti-Stat3 pAb recognizes the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 are recognized by anti-LMP-1 purified affinity antiserum with which the wires were probed.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 are recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized in the immunoprecipitatome with anti-LMP-1 purified affinity antiserum, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution are recognized by anti-LMP-1 anti-LMP-1 purified affinity with which the threads were probed.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution are recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution was recognized by anti-LMP-1 anti-LMP-1 purified affinity by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution was recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution, will be recognized in the immunoprecipitaiton with anti-LMP-1 anti-LMP-1 purified affinity as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 are recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 will be recognized in immunoprecipitatio with anti-LMP-1 purified affinity antiserum, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200, could be recognized in the immunoprecipitaiton with anti-LMP-1 antisembly purified as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200, could be recognized in the immunoprecipitaiton with anti-LMP-1 purified affinity antiserum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution are recognized by anti-LMP-1 antisembly purified with which the threads were probed.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 are recognized by polyclonal anti-LMP-1 affinity antisumption with which the threads were probed.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 could be recognized in immunoprecipitatio with polyclonal anti-LMP-1 affinity antisumption, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 is recognized by polyclonal anti-LMP-1 affinity antisumption that the litters were probed.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 will be recognized by polyclonal anti-LMP-1 affinity antisumption.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution is recognized by anti-LMP-1 anti-LMP-1 purified affinity that the litters were probed.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution were recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution will be recognized by the anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution, cannot is recognized in the immunoprecipitaiton with anti-LMP-1 anti-LMP-1 purified affinity as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>four different specific antibodies recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">four different specific antibodies</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>heptameric in other arrangements has been recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>heptameric in other arrangements, will be recognized in the immunoprecipitaiton with NarL protein as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>heptamers in other arrangements are recognized by NarL protein with which the threads were probed.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>heptamers in other arrangements are recognized by the NarL protein with which the threads were probed.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>heptamers in other arrangements has been recognized by the NarL protein.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>heptamers in other arrangements is recognized by NarL protein by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>heptamers in other arrangements is recognized by NarL protein that the litters were probed.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>heptamers in other arrangements was recognized by NarL protein by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>heptamers in other arrangements was recognized in the immunoprecipitatome with the NarL protein, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>heptamers in other arrangements will be recognized in immunoprecipitatio with NarL protein, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>heptamers in other arrangements will be recognized in immunoprecipitatio with the NarL protein, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>heptamers in other arrangements, cannot is recognized in immunoprecipitatio with NarL protein, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>monoclonal antibody also binds to these sites 7-2-7, but, unlike NarP, it also recognized STAT1 N-terminal .</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>monoclonal antibody are able to recognize N-terminus STAT1 in regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>monoclonal antibody binds to these sites 7-2-7, but, unlike NarP, it also recognizes STAT1 N-terminus .</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>monoclonal antibody has also joined these 727 sites but, unlike NarP, has also recognized STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>monoclonal antibody recognized N-terminus STAT1 in regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>monoclonal antibody recognizes STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>monoclonal antibody recognizes STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>monoclonal antibody specifically recognized STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>monoclonal antibody that has recognized STAT1 N-terminal was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>monoclonal antibody that recognized STAT1 N-terminal was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>most of the regulators belonging to the AraC/XylS family also binds to these sites 7-2-7, but, unlike NarP, it also recognized multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>most of the regulators belonging to the AraC/XylS family binds to these sites 7-2-7, but, unlike NarP, it also recognizes multiple linkage site .</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>most of the regulators belonging to the AraC/XylS family can recognize multi-binding sites in regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>most of the regulators belonging to the AraC/XylS family recognized multiple linkage site in the regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>most of the regulators belonging to the AraC/XylS family recognized multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>most of the regulators belonging to the AraC/XylS family recognizes multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>most of the regulators belonging to the AraC/XylS family recognizes multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>most of the regulators belonging to the AraC/XylS family specifically recognized multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>most of the regulators belonging to the AraC/XylS family that has recognized multi-binding sites was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>most of the regulators belonging to the AraC/XylS family that recognized multiple-link location was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>most of the regulators belonging to the AraC/XylS family that recognizes multi-binding sites is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>most regulators belonging to the AraC/XylS family that recognizes multiple binding sites is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>most regulators belonging to the AraC/XylS family that recognizes multiple binding sites is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>multi-binding sites will be recognized in immunoprecipitatio with most of the regulators belonging to the AraC/XylS family, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>multi-binding sites, will be recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>multiple binding sites has been recognized by most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>multiple binding sites will be recognized in immunoprecipitatio with most regulators belonging to the AraC/XylS family, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>multiple connection site has been recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>multiple connection site is recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>multiple connection site was recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>multiple connection site, could be recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>multiple connection site, was unrecognized in immunoprecipitatio with most of the regulators belonging to the AraC/XylS family, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>multiple linkage site was recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>multiple-link location are recognized by most of the regulators belonging to the AraC/XylS family with which the wires were probed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>multiple-link location was recognized in the immunoprecipitatome with most of the regulators belonging to the AraC/XylS family, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>multiple-link location will be recognized by the most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>multiple-link location, has been recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>polyclonal anti-CD40 anti-rabbit antisound binds to these sites 7-2-7, but, unlike NarP, it also recognizes C-term of CD40 at a 1:500 dilution .</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>polyclonal anti-CD40 anti-rabbit antisound can recognize C-term of CD40 at a 1:500 dilution in regulated promoters.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>polyclonal anti-CD40 anti-rabbit antisound is able to recognize C-term of CD40 at a 1:500 dilution in regulated promoters.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>polyclonal anti-CD40 anti-rabbit antisound will recognize C-term of CD40 at a 1:500 dilution in regulated promoters.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle are recognized by D1 antibody of human autoantigen anti-64kD with which the wires were probed.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is recognized by D1 anti-64kD human autoantigen by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is recognized by D1 anti-64kD human autoantigen that the litters were probed.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is recognized by D1 anti-64kD human autoantigen.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is recognized by D1 antibody of human autoantigen anti-64kD that the litters were probed.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle were recognized by D1 antibody of human autoantigen anti-64kD.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, cannot is recognized in the immunoprecipitaiton with D1 anti-64kD human autoantigen as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, cannot is recognized in the immunoprecipitaiton with D1 antibody of human autoantigen anti-64kD as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle is recognized by anti-64kD antibodies of human autoantigen D1 by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle were recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle will be recognized by the anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle, could be recognized in the immunoprecipitaiton with anti-64kD antibodies of human autoantigen D1 as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>proteins are able to recognize short reasons within the protected region in regulated promoters.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>proteins binds to these 727 sites but, unlike NarP, will also recognize short reasons within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>short motives within the protected region are recognized by proteins with which the threads were probed.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>short motives within the protected region are recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>short motives within the protected region could be recognized in immunoprecipitatio with proteins, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>short motives within the protected region is recognized by proteins that the litters were probed.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>short motives within the protected region, could be recognized in the immunoprecipitaiton with proteins as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>short motives within the protected region, has been recognized in the immunoprecipitaiton with proteins as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>short reasons within the protected region is recognized by proteins by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>short reasons within the protected region was recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>short reasons within the protected region, has been recognized in the immunoprecipitaiton with proteins as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>short reasons within the protected region, was not recognized in the immunoprecipitaiton with proteins as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>the NarL protein recognizes heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>the RNA ribosomal gene promoter is recognized by the upstream eukaryotic binding factor (UBF) that the litters were probed.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>the RNA ribosomal gene promoter will be recognized in immunoprecipitatio with the upstream eukaryotic binding factor (UBF), since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>the RNA ribosomal gene promoter, has been recognized in the immunoprecipitaiton with the upstream eukaryotic binding factor (UBF) as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>the RNA ribosomal gene promoter, was unrecognized in immunoprecipitatio with the upstream eukaryotic binding factor (UBF), because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>the STAT1 N-terminal are recognized by a monoclonal antibody with which the wires were probed.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>the STAT1 N-terminal is recognized by a monoclonal antibody that the litters were probed.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>the activator complex cAMP-CRP also binds to these 727 sites but, unlike NarP, also recognized two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>the activator complex cAMP-CRP binds to these sites 7-2-7, but, unlike NarP, it also recognizes two sites in tsx-p2 .</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>the activator complex cAMP-CRP has also joined these 727 sites but, unlike NarP, has also recognized two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>the activator complex cAMP-CRP recognized two sites in tsx-p2 in the regulated promoters.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>the activator complex cAMP-CRP that recognizes two sites in tsx-p2 is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>the cAMP-CRP activator complex binds to these sites 7-2-7, but, unlike NarP, it also recognizes two sites in tsx-p2 .</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>the cAMP-CRP activator complex is able to recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>the cAMP-CRP activator complex recognizes two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>the cAMP-CRP activator complex that has recognized two sites in tsx-p2 was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>the eukaryotic binding factor upstream (UBF) also binds to these sites 7-2-7, but, unlike NarP, it also recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>the eukaryotic binding factor upstream (UBF) binds to these sites 7-2-7, but, unlike NarP, it also recognizes the promoter of the RNA ribosomal gene .</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>the eukaryotic binding factor upstream (UBF) recognized the promoter of the RNA ribosomal gene in the regulated promoters.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>the eukaryotic binding factor upstream (UBF) recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>the eukaryotic binding factor upstream (UBF) specifically recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>the lowest form of Stat3, Stat3Beta are recognized by anti-Stat3 pAb with which the threads were probed.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>the lowest form of Stat3, Stat3Beta are recognized by anti-Stat3 pAb with which the wires were probed.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>the lowest form of Stat3, Stat3Beta is recognized by anti-Stat3 pAb by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>the lowest form of Stat3, Stat3Beta is recognized by anti-Stat3 pAb by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>the lowest form of Stat3, Stat3Beta will be recognized by anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>the promoter of the RNA ribosomal gene are recognized by the eukaryotic binding factor upstream (UBF) with which the wires were probed.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>the promoter of the RNA ribosomal gene is recognized by the eukaryotic binding factor upstream (UBF) by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>the promoter of the RNA ribosomal gene is recognized by the eukaryotic binding factor upstream (UBF) that the litters were probed.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>the promoter of the RNA ribosomal gene was recognized in the immunoprecipitatome with the eukaryotic binding factor upstream (UBF), because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>the promoter of the RNA ribosomal gene will be recognized by the the eukaryotic binding factor upstream (UBF).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>the promoter of the RNA ribosomal gene, cannot is recognized in immunoprecipitatio with the upstream eukaryotic binding factor (UBF), as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>the promoter of the RNA ribosomal gene, has been recognized in the immunoprecipitaiton with the eukaryotic binding factor upstream (UBF) as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>the upstream eukaryotic binding factor (UBF) binds to these sites 7-2-7, but, unlike NarP, it also recognizes the RNA ribosomal gene promoter .</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>the upstream eukaryotic binding factor (UBF) recognized the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>the upstream eukaryotic binding factor (UBF) specifically recognized the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>the upstream eukaryotic binding factor (UBF) specifically recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>the upstream eukaryotic binding factor (UBF) that recognizes the promoter of the RNA ribosomal gene is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>two sites in tsx-p2 are recognized by activating complex cAMP-CRP.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>two sites in tsx-p2 are recognized by activating the cAMP-CRP complex with which the threads were probed.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>two sites in tsx-p2 are recognized by activating the cAMP-CRP complex.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>two sites in tsx-p2 are recognized by activator complex cAMP-CRP with which the wires were probed.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>two sites in tsx-p2 are recognized by the activator complex cAMP-CRP with which the threads were probed.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>two sites in tsx-p2 is recognized by activating the cAMP-CRP complex that the litters were probed.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>two sites in tsx-p2 is recognized by the activator complex cAMP-CRP by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>two sites in tsx-p2 is recognized by the activator complex cAMP-CRP.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>two sites in tsx-p2 was recognized by activating the cAMP-CRP complex by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>two sites in tsx-p2 were recognized by activating complex cAMP-CRP.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>two sites in tsx-p2 will be recognized by the activator complex cAMP-CRP.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>two sites in tsx-p2 will be recognized by the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>two sites in tsx-p2 will be recognized by the the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>two sites in tsx-p2 will be recognized in immunoprecipitatio with activator complex cAMP-CRP, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>two sites in tsx-p2, was not recognized in the immunoprecipitaiton with activator complex cAMP-CRP as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), has recognized a number of Ags and activated the RNA polymerase I-mediated transcription through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), recognized a series of Ags and activated the transcription mediated by RNA polymerase I through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by autologous serum are the ones indicated.</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by the autological serum are the ones indicated.</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by the autologous serum are the ones indicated.</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by RNA supply apparatus are indicated.</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by class I melanoma-specific T cells are indicated.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by the RNA supply apparatus are indicated.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by the autologous serum are indicated.</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by Class I melanoma-specific T cells are the ones indicated.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by Class and T cells specific to melanoma are as given.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by autological serum are as given.</text>
                    <arg n="0">autological serum</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by autologous serum are the ones indicated.</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by the autological serum are as given.</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by autologous serum are indicated.</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by one of the two monoclonal antibodies are the ones indicated.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>Blots were surveyed with Class I melanoma-specific T cells recognizing a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>Blots were surveyed with one of two monoclonal antibodies recognizing COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>COOH-terminal epitopes are recognized by one of the two monoclonal antibodies with which the threads were probed.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>COOH-terminal epitopes are recognized by one of the two monoclonal antibodies.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>COOH-terminal epitopes is recognized by one of the two monoclonal antibodies by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>COOH-terminal epitopes is recognized by one of two monoclonal antibodies by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>COOH-terminal epitopes was recognized by one of two monoclonal antibodies by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>COOH-terminal epitopes will be recognized by one of the two monoclonal antibodies.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>COOH-terminal epitopes will be recognized by the one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>COOH-terminal epitopes, could be recognized in the immunoprecipitaiton with one of the two monoclonal antibodies as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>COOH-terminal epitopes, has been recognized in the immunoprecipitaiton with one of two monoclonal antibodies as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>COOH-terminal epitopes, was unrecognized in immunoprecipitatio with one of two monoclonal antibodies, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>Class I melanoma-specific T cells also binds to these 727 sites but, unlike NarP, also recognized a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>Class I melanoma-specific T cells binds to these 727 sites but, unlike NarP, will also recognize a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>Class I melanoma-specific T cells binds to these 727 sites but, unlike NarP, will also recognize a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>Class I melanoma-specific T cells specifically recognized a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>Class I melanoma-specific T cells that recognizes a series of Ags is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>Class and T cells specific to melanoma are able to recognize a series of Ags in regulated promoters.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>Class and T cells specific to melanoma recognizes a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that one of the two monoclonal antibodies can recognize COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that one of two monoclonal antibodies can recognize cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that Class I melanoma-specific T cells recognized a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that RNA supply apparatus has recognized normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that autologous serum recognized epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that one of the two monoclonal antibodies has recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that one of the two monoclonal antibodies recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the autological serum recognized epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the reverse transcription apparatus has recognized the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where COOH-terminal epitopes is recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where a series of Ags is recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epitopes was recognized by autological serum.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with autological serum which recognizes epitopes, and by Western blotting</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with one of the two monoclonal antibodies which recognizes COOH-terminal epitopes, and by Western blotting</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the autologous serum which recognized epitopes and by the western inflorescence.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the reverse transcription apparatus which recognized the normal junction of slice, and by Western blotting</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where cooled-terminal epitopes was recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where epitopes was recognized by autological serum.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where the epitopes was recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where the normal junction of slice was recognized by the reverse transcription apparatus.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>It is shown that Class I melanoma-specific T cells has recognized a number of Ags that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>It is shown that the autologous serum has recognized epitopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that Class and T cells specific to melanoma has recognized a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that Class and T cells specific to melanoma recognized a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that RNA supply apparatus are able to recognize normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that RNA supply apparatus recognized normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that autological serum are able to recognize epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that autologous serum recognized epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that autologous serum recognized the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that one of the two monoclonal antibodies can recognize COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that one of the two monoclonal antibodies recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that one of two monoclonal antibodies are able to recognize COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the reverse transcription apparatus has recognized the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that Class I melanoma-specific T cells are able to recognize a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that Class and T cells specific to melanoma are able to recognize a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>RNA supply apparatus binds to these sites 7-2-7, but, unlike NarP, it also recognizes normal slice ligation .</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>RNA supply apparatus has also joined these 727 sites but, unlike NarP, has also recognized normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>RNA supply apparatus recognizes normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>RNA supply apparatus that has recognized normal slice ligation was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>The blots were investigated with autologous serum that recognized epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>The blots were investigated with the reverse transcription apparatus that recognized the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>The blots were probed with Class I melanoma-specific T cells that can recognize a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>The blots were probed with Class and T cells specific to melanoma recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>The blots were probed with RNA supply apparatus recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>The blots were probed with class I melanoma-specific T cells that can recognize A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>The blots were probed with class I melanoma-specific T cells that can recognize a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>The blots were probed with one of the two monoclonal antibodies that can recognize A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>The blots were probed with the RNA supply apparatus that can recognize the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>The blots were probed with the autological serum recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>The blots were probed with the autological serum that recognized A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>The blots were probed with the autologous serum that can recognize epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with autological serum that recognizes epitopes and by western blotting.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with the RNA supply apparatus that recognizes the normal splice binding and by western blotting.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where cooled-terminal epitopes is recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>The the normal splice binding was recognized by the the RNA supply apparatus acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>These bands can be detected with Class I melanoma-specific T cells that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>These bands can be detected with Class I melanoma-specific T cells that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>These bands can be detected with RNA supply apparatus that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>These bands can be detected with RNA supply apparatus that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>These bands can be detected with autologous serum that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>These bands can be detected with class I melanoma-specific T cells that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>These bands can be detected with one of the two monoclonal antibodies that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>These bands can be detected with the autological serum that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>These bands can be detected with the autologous serum that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>We show that Class I melanoma-specific T cells recognized a series of Ags that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>We show that Class I melanoma-specific T cells recognized a series of Ags that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>We show that RNA supply apparatus recognized normal slice ligation that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>We show that RNA supply apparatus will recognize normal slice ligation that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>We show that autological serum recognized epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>We show that autologous serum recognized epitopes that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>We show that one of two monoclonal antibodies recognized COOH-terminal epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>We show that one of two monoclonal antibodies recognized cooled-terminal epitopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>We show that the RNA supply apparatus will recognize the normal splice binding that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>We show that the autologous serum recognized epitopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>a number of Ags are recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>a number of Ags has been recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>a number of Ags is recognized by Class I melanoma-specific T cells by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>a series of Ags are recognized by class I melanoma-specific T cells with which the wires were probed.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>a series of Ags could be recognized in immunoprecipitatio with Class I melanoma-specific T cells, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>a series of Ags has been recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>a series of Ags is recognized by Class I melanoma-specific T cells by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>a series of Ags is recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>a series of Ags is recognized by Class and T cells specific to melanoma by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>a series of Ags is recognized by Class and T cells specific to melanoma that the litters were probed.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>a series of Ags is recognized by class I melanoma-specific T cells that the litters were probed.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>a series of Ags is recognized by class I melanoma-specific T cells.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>a series of Ags was recognized by Class I melanoma-specific T cells by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>a series of Ags will be recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>a series of Ags will be recognized in immunoprecipitatio with Class and T cells specific to melanoma, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>a series of Ags, could be recognized in the immunoprecipitaiton with Class and T cells specific to melanoma as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>a series of Ags, has been recognized in the immunoprecipitaiton with class I melanoma-specific T cells as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>a series of Ags, was not recognized in the immunoprecipitaiton with Class I melanoma-specific T cells as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>a series of Ags, was unrecognized in immunoprecipitatio with Class I melanoma-specific T cells, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>a series of Ags, will be recognized in the immunoprecipitaiton with Class I melanoma-specific T cells as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>a series of Ags, will be recognized in the immunoprecipitaiton with Class and T cells specific to melanoma as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>a series of Ags, will be recognized in the immunoprecipitaiton with class I melanoma-specific T cells as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>autological serum binds to these 727 sites but, unlike NarP, will also recognize epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>autological serum recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">autological serum</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>autological serum recognized epitopes in regulated promoters.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>autological serum recognized epitopes in the regulated promoters.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>autological serum recognizes epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>autological serum that recognizes epitopes is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>autologous serum also binds to these 727 sites but, unlike NarP, also recognized epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>autologous serum binds to these 727 sites but, unlike NarP, will also recognize the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>autologous serum is able to recognize epitopes in regulated promoters.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>autologous serum recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>autologous serum recognized the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>autologous serum specifically recognized epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>autologous serum that recognizes epitopes is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>autologous serum that recognizes the epitopes is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>class I melanoma-specific T cells also binds to these sites 7-2-7, but, unlike NarP, it also recognized a series of Ags .</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>class I melanoma-specific T cells has also joined these 727 sites but, unlike NarP, has also recognized a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>class I melanoma-specific T cells that recognized a series of Ags was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>class I melanoma-specific T cells that recognizes a series of Ags is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>cooled-terminal epitopes are recognized by one of two monoclonal antibodies with which the wires were probed.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>cooled-terminal epitopes is recognized by one of two monoclonal antibodies by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>epiptopes will be recognized by the autological serum.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>epiptopes, cannot is recognized in the immunoprecipitaiton with the autological serum as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>epitopes are recognized by autologous serum with which the threads were probed.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>epitopes is recognized by autological serum by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>epitopes is recognized by autologous serum by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>epitopes is recognized by autologous serum that the litters were probed.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>epitopes is recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>epitopes is recognized by the autologous serum by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>epitopes was recognized by autological serum.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>epitopes will be recognized by the autological serum.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>epitopes, cannot is recognized in immunoprecipitatio with autological serum, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>epitopes, was not recognized in the immunoprecipitaiton with the autologous serum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>epitopes, will be recognized in the immunoprecipitaiton with autologous serum as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>normal slice ligation are recognized by RNA supply apparatus with which the threads were probed.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>normal slice ligation could be recognized in immunoprecipitatio with RNA supply apparatus, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>normal slice ligation is recognized by RNA supply apparatus that the litters were probed.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>normal slice ligation was recognized by RNA supply apparatus.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>normal slice ligation will be recognized by the RNA supply apparatus.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>normal slice ligation, cannot is recognized in the immunoprecipitaiton with RNA supply apparatus as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>normal slice ligation, could be recognized in the immunoprecipitaiton with RNA supply apparatus as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>one of the two monoclonal antibodies are able to recognize COOH-terminal epitopes in regulated promoters.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>one of the two monoclonal antibodies that recognizes COOH-terminal epitopes is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>one of two monoclonal antibodies are able to recognize cooled-terminal epitopes in regulated promoters.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>one of two monoclonal antibodies binds to these sites 7-2-7, but, unlike NarP, it also recognizes cooled-terminal epitopes .</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>one of two monoclonal antibodies has also joined these 727 sites but, unlike NarP, has also recognized cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>one of two monoclonal antibodies recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>one of two monoclonal antibodies specifically recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>one of two monoclonal antibodies that recognized COOH-terminal epitopes was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>the RNA supply apparatus that recognizes the normal splice binding is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>the RNA supply apparatus that recognizes the normal splice binding is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>the autological serum recognized epiptopes in the regulated promoters.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>the autologous serum is able to recognize epitopes in regulated promoters.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>the epitopes has been recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>the epitopes is recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>the epitopes, has been recognized in the immunoprecipitaiton with autologous serum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>the normal junction of slice could be recognized in immunoprecipitatio with the reverse transcription apparatus, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>the normal junction of slice has been recognized by the reverse transcription apparatus.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>the normal junction of slice is recognized by the reverse transcription apparatus by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>the normal junction of slice, was not recognized in the immunoprecipitaiton with the reverse transcription apparatus as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>the normal splice binding are recognized by the RNA supply apparatus.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>the normal splice binding could be recognized in immunoprecipitatio with the RNA supply apparatus, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>the normal splice binding were recognized by the RNA supply apparatus.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>the normal splice binding will be recognized in immunoprecipitatio with the RNA supply apparatus, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>the normal splice binding, could be recognized in the immunoprecipitaiton with the RNA supply apparatus as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>the normal splice binding, was unrecognized in immunoprecipitatio with the RNA supply apparatus, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>the reverse transcription apparatus also binds to these 727 sites but, unlike NarP, also recognized the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>the reverse transcription apparatus specifically recognized the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>the reverse transcription apparatus will recognize the normal junction of slice in regulated promoters.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
